MEGF0444A + bevacizumab + oxaliplatin + folinic acid + 5-fluorouracil

**MEGF0444A + bevacizumab + oxaliplatin + folinic acid + 5-fluorouracil** is an investigational multi-agent combination regimen evaluated in phase 2 clinical trials for the first-line treatment of previously untreated metastatic colorectal cancer. The regimen combines: - MEGF0444A, a monoclonal antibody targeting an undisclosed antigen likely involved in tumor angiogenesis or growth, in combination with - bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), - oxaliplatin, a platinum-based cytotoxic chemotherapeutic, - folinic acid (leucovorin), a biomodulator enhancing 5-fluorouracil activity, and - 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase to disrupt DNA synthesis. The combination matches the “mFOLFOX-6 + bevacizumab” backbone, with experimental addition of MEGF0444A, for extended cycles until progression. MEGF0444A was developed and trialed by Genentech as an anti-cancer biologic. The combination was investigated for its efficacy/safety over standard regimens[1][2].